Coherent Biopharma Suzhou Co. Ltd. is a business that specializes in producing biological products. It was established by Bao Hua Huang on March 3rd, 2016 and has its headquarters located in Suzhou, China.

Tags

Neoplasms

Urogenital Diseases

Skin and Musculoskeletal Diseases

Small molecule-drug conjugates

Monoclonal antibody

Proteolysis-targeting chimeras (PROTAC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	8
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule-drug conjugates	3
Monoclonal antibody	2
Proteolysis-targeting chimeras (PROTAC)	1
Unknown	1
Radiopharmaceuticals and diagnostic agent	1

Top 5 Target	Count

FOLR1 x TRPV6	1
CLDN18.2(Claudin 18.2)	1
FOLR1 x TRPV6 x Top I	1
FOLR1 x TRPV6 x Tubulin	1
TRPV6(Transient receptor potential cation channel subfamily V member 6)	1

Drugs associated with Coherent Biopharma Suzhou Co., Ltd.

CBP-1008

Target

FOLR1 x TRPV6 x Tubulin

Mechanism

FOLR1 agonists [+3]

Active Org.

Coherent Biopharma Suzhou Co., Ltd.Startup

Originator Org.

Coherent Biopharma Suzhou Co., Ltd.Startup

Active Indication

Breast Cancer [+5]

Inactive Indication-

Drug Highest PhasePhase 2/3

First Approval Ctry. / Loc.-

First Approval Date-

CBP-1019

Target

FOLR1 x TRPV6 x Top I

Mechanism

FOLR1 antagonists [+2]

Active Org.

Coherent Biopharma Suzhou Co., Ltd.Startup [+1]

Originator Org.

Coherent Biopharma Suzhou Co., Ltd.Startup

Active Indication

Advanced Malignant Solid Neoplasm [+11]

Inactive Indication-

Drug Highest PhasePhase 1/2

First Approval Ctry. / Loc.-

First Approval Date-

CBP-1018

Target

FOLR1 x TRPV6

Mechanism

FOLR1 antagonists [+2]

Active Org.

Coherent Biopharma Suzhou Co., Ltd.Startup

Originator Org.

Coherent Biopharma Suzhou Co., Ltd.Startup

Active Indication

Advanced Malignant Solid Neoplasm [+2]

Inactive Indication

Lung Cancer

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Coherent Biopharma Suzhou Co., Ltd.

CTR20231987

/ RecruitingPhase 1

评价注射用CBP-1019在晚期胸部恶性肿瘤患者中安全性和耐受性、药代动力学及初步疗效的Ⅰ期临床研究

[Translation] A Phase I clinical study to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of CBP-1019 for injection in patients with advanced thoracic malignancies

1）Ⅰa期：评估注射用CBP-1019在晚期肺癌患者中的安全性和耐受性；确定CBP-1019在晚期肺癌患者的最大耐受剂量（MTD）和Ⅱ期推荐剂量（RP2D）； 2）Ⅰb期：评估注射用CBP-1019在晚期肺癌患者中的客观缓解率（ORR）。

[Translation]

1) Phase Ia: Evaluate the safety and tolerability of CBP-1019 for injection in patients with advanced lung cancer; determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of CBP-1019 in patients with advanced lung cancer; 2) Phase Ib: Evaluate the objective response rate (ORR) of CBP-1019 for injection in patients with advanced lung cancer.

Start Date16 Oct 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

CTR20231450

/ RecruitingPhase 1

评价注射用CBP-1019在晚期恶性实体瘤患者中安全性和耐受性、药代动力学及初步疗效的非随机、开放、首次用于人体的国际多中心Ⅰ/Ⅱ期临床研究

[Translation] A non-randomized, open-label, first-in-human, international, multicenter Phase I/II clinical study to evaluate the safety and tolerability, pharmacokinetics, and preliminary efficacy of CBP-1019 for injection in patients with advanced malignant solid tumors

1）Ⅰa期：评估CBP-1019在晚期恶性肿瘤患者中的安全性和耐受性；确定CBP-1019在晚期恶性肿瘤患者的最大耐受剂量（MTD）和Ⅱ期推荐剂量（RP2D）； 2）Ⅰb/Ⅱ期：评估CBP-1019在晚期恶性肿瘤患者中的客观缓解率（ORR）。

[Translation]

1) Phase Ia: Evaluate the safety and tolerability of CBP-1019 in patients with advanced malignant tumors; Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of CBP-1019 in patients with advanced malignant tumors; 2) Phase Ib/II: Evaluate the objective response rate (ORR) of CBP-1019 in patients with advanced malignant tumors.

Start Date14 Aug 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

NCT05830097

/ RecruitingPhase 1/2

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.

Start Date14 Mar 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

100 Clinical Results associated with Coherent Biopharma Suzhou Co., Ltd.

0 Patents (Medical) associated with Coherent Biopharma Suzhou Co., Ltd.

Literatures (Medical) associated with Coherent Biopharma Suzhou Co., Ltd.

22 Mar 2024·Cancer Research

Abstract 6042: CBP-8008: A first-in-class targeted pan-Bet protein degradation therapy using bi-specific XDC (Bi-XDC) technology for TNBC and mCRPC

Author: Wang, Tao ; Pan, Fan ; Huang, Robert ; Wang, Guitao ; Zhang, Zhiguang

AbstractBi-XDC is a breakthrough cellular targeting technology using multi-targeting ligands to effectively deliver the payload to and into specific cells. Several anticancer Bi-ligand drug conjugates including CBP-1008, CBP-1018, and CBP-1019 have been brought into various clinical stages in China and US. Targeted protein degradation molecules can degrade previously “undruggable” target proteins through their catalytic mechanism of action. The field target protein degradation has evolved since 2001, and more than 20 PROTACs are under clinical trials at different stages.To increase the efficacy vs. tolerability window, we combine Bi-XDC technology and the catalytic approach of targeted protein degradation, to form C-PROTAC, by taking advantage of our privileged Bi-XDC technology and PROTAC’s degradation property. Further medicinal chemistry optimization, spacer optimization, and evaluation of many linker payloads led to the identification of our preclinical candidate CBP-8008, a highly potent pan-Bet protein degrader conjugated to bi-ligand via a cleavable linker.A small panel of cell lines was screened to identify which tumors were sensitive to the pan-Bet protein degradation. All the tested breast cancer and prostate cell lines were the most sensitive to the payload. CBP-8008 had a high affinity to the Prostate Specific Membrane Antigen (PSMA) and the folate receptor alpha (FRα). Much more CBP-8008 were binding the 293T-FP which overexpress both FR-α and PSMA than the cell lines which only express one target (293T-F or 293T-P) or negative cell line (293T). CBP-8008 can quickly enter cells through endocytosis after treatment for 15 min, and degradation of BRD2, BRD3, and BRD4 was observed in MDA-MB-231 after 6 h, which was similar to its payload. The compound was very stable in mouse and human plasma in vitro, and limited free payload was detected which potentially avoids hematotoxicity in clinical. In the tumor-beaning mice DMPK study, fewer free payload was detected in 6 hours while much more free payload was detected in the tumor than in the blood and the time was extended to 72 hours after a single dose treatment. We evaluated CBP-8008 in TNBC and mCRPC xenograft model and robust efficacy was observed as lower as 3 MPK, significantly better than BMS-986158, a potent Bet inhibitor in clinical.In conclusion: CBP-8008 is currently in preclinical development as a potential first-in-class pan-Bet protein degradation therapy using Bi-XDC technology for TNBC and mCRPCCitation Format: Tao Wang, Zhiguang Zhang, Guitao Wang, Fan Pan, Robert Huang. CBP-8008: A first-in-class targeted pan-Bet protein degradation therapy using bi-specific XDC (Bi-XDC) technology for TNBC and mCRPC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6042.

15 Jun 2022·Cancer Research

Abstract 6275: Evaluation of FRα/TRPV6 expression in gynecological cancer

Author: Wu, Lingying ; Tan, Wei ; Li, Yifan ; Huang, Baohua ; Li, Ning ; Teng, Yan

AbstractPurpose:Folate Receptor Alpha (FRα) is highly expressed in multiple malignancies, including ovarian, NSCLC and breast cancer. Transient Receptor Potential Vanilloid 6(TRPV6) is upregulated in breast, ovarian and prostate cancer. However, there is no report on expression and correlation between expression of the two markers. Since both markers are highly expressed in ovarian cancer, it is of great interest to evaluate expression of FRα and TRPV6 in a panel of gynecological cancer, including those major subtypes.Method:We have collected 200+ FFPE samples achieved in pathology core at National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, including high grade and low grade serous ovarian cancer and clear cell ovarian cancer et al. Using validated IHC assays, expression of both FRα and TRPV6 are evaluated.Result:Various levels of FRα and TRPV6 express in different histological subtypes of ovarian cancer. High grade serous ovarian cancer expresses the highest levels of FOLR1, which is about 2.8 and 2 folds over that of low-grade ovarian cancer and that of clear cancer ovarian cancer, respectively. The highest levels of TRPV6 expression are observed in clear cell ovarian cancer, which is 2.6 and 1.6 folds over that observed in low grade ovarian cancer and that observed in high grade ovarian cancer, respectively. The two biomarker expression is overlapped in about 45% of all samples analyzed. A comparison of samples from patients with or without good response to neoadjuvant therapy reveals samples with poor responses tend to express higher levels of FRα than those with good responses do. Addition evaluation and analysis are still on-going.Conclusion: FRα and TRPV6 are highly express in gynecological cancer. Evaluation of their expression is of great value for molecularly-targeted therapies for those two targets and provide a precision medicine option for the clinical development for such drugs.Citation Format: Ning Li, Yifan Li, Wei Tan, Yan Teng, Baohua Huang, Lingying Wu. Evaluation of FRα/TRPV6 expression in gynecological cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6275.

01 Jun 2022·Journal of Clinical Oncology

An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.

Author: Chai, Xiaoyan ; Huang, Robert ; Teng, Yan ; Zhou, Liyan ; Yu, Jiangang ; Li, Kaiwen ; Lai, Xiuping ; Shi, Yehui ; Wu, Junyan ; Ye, Suiwen ; Huang, Hai

TPS2694 Background: Folate-receptor 1 (FOLR1) and prostate specific membrane antigen (PSMA) are overexpressed on tumor and angiogenic endothelial cells in solid tumors, including prostate cancer, renal cell cancer and lung cancer. CBP-1018 is a first-in-class bi-ligand drug conjugate targeting to both FOLR1 and PSMA, with a tubulin inhibitor payload, monomethyl auristatin E (MMAE). We herein introduce its first-in-human study which is designed based on the significant anti-tumor potency and acceptable safety profile in nonclinical studies. Methods: This study is a phase Ⅰa/Ⅰb, multicenter, open-label study enrolling patients with advanced solid tumor relapsed after previous standard therapies. The primary objective is to assess CBP-1018 safety, tolerability, dose limiting toxicity and maximum tolerated dose. Preliminary efficacy including objective response rate, duration of response and progression-free survival will be observed. Pharmacokinetics, immunogenicity and biomarkers will be also evaluated. This study includes 2 parts: Ⅰa (Dose Escalation) and Ⅰb (Dose Expansion). CBP-1018 is administrated iv Q2W (4 weeks/cycle) in Ⅰa, with accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i3+3 design at following doses (0.08 mg/kg, 0.10 mg/kg, 0.12 mg/kg and 0.14mg/kg, etc.). Subjects will be enrolled in 4 cohorts in Ⅰb: metastatic castration resistant prostate cancer, advanced renal cell cancer, advanced lung squamous cell cancer, and other advanced solid tumors. Efficacy will be assessed every 8 weeks (±7days) according to RECIST 1.1, PCWG3 and PSA assessment (only for prostate cancer). Treatment will be continued untill disease progression or intolerable toxicity. Enrollment has been started in Nov. 2021 and is ongoing. Clinical trial information: NCT04928612.

100 Deals associated with Coherent Biopharma Suzhou Co., Ltd.

100 Translational Medicine associated with Coherent Biopharma Suzhou Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 31 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

IND Application

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CBP-1008 ( FOLR1 x TRPV6 x Tubulin )	Ovarian Cancer More	Phase 3 Clinical
CBP-1019 ( FOLR1 x TRPV6 x Top I )	Lung Cancer More	Phase 2 Clinical
CBP-1018 ( FOLR1 x TRPV6 )	Advanced Malignant Solid Neoplasm More	Phase 1
CBP-8088	Neoplasms More	IND Application
CBP-1203	Solid tumor More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis